Pranidipine: Difference between revisions
CSV import |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 23: | Line 23: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Pranidipine_structure.svg|Pranidipine structure | |||
</gallery> | |||
Latest revision as of 00:57, 17 March 2025
Pranidipine is a calcium channel blocker that is used primarily in the treatment of hypertension. It is a third-generation calcium channel blocker, developed in Japan and sold under the brand name Acalas.
Mechanism of Action[edit]
Pranidipine works by inhibiting the influx of calcium ions into cardiac muscle and smooth muscle cells. This inhibition leads to a decrease in muscle contraction, which in turn reduces the resistance in blood vessels and lowers blood pressure.
Pharmacokinetics[edit]
After oral administration, pranidipine is rapidly absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism in the liver, resulting in a low bioavailability. The drug is primarily excreted in the urine.
Side Effects[edit]
Common side effects of pranidipine include headache, flushing, and dizziness. Less common side effects may include palpitations, abdominal pain, and rash.
Contraindications[edit]
Pranidipine is contraindicated in patients with known hypersensitivity to the drug or any of its components. It is also contraindicated in patients with severe cardiac insufficiency.
Interactions[edit]
Pranidipine may interact with other drugs, including other calcium channel blockers, beta blockers, and ACE inhibitors. These interactions can lead to an increased risk of side effects or a decrease in the effectiveness of the drug.
References[edit]
<references />


